Related references
Note: Only part of the references are listed.Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)
Wei Zhang et al.
JOURNAL OF CHROMATOGRAPHY A (2010)
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies
M. Wasif Saif et al.
PHYTOMEDICINE (2010)
The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity
Wing Lam et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqi Tang (HQT) and PHY906
Robert Tilton et al.
Chinese Medicine (2010)
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
Andrea Worschech et al.
BMC GENOMICS (2009)
Cytochrome c/cardiolipin relations in mitochondria: a kiss of death
Valerian E. Kagan et al.
FREE RADICAL BIOLOGY AND MEDICINE (2009)
Evidence from the Cochrane Collaboration for Traditional Chinese Medicine Therapies
Eric Manheimer et al.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2009)
Bioactivity-guided identification and cell signaling technology to delineate the immunomodulatory effects of Panax ginseng on human promonocytic U937 cells
Davy C. W. Lee et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
NOD2, RIP2 and IRF5 Play a Critical Role in the Type I Interferon Response to Mycobacterium tuberculosis
Amit K. Pandey et al.
PLOS PATHOGENS (2009)
The IRF family transcription factors in immunity and oncogenesis
Tomohiko Tamura et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs
Jeong Heon Lee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
IMMUNOLOGICAL REVIEWS (2007)
High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy
Xiang Da (Eric) Dong et al.
JOURNAL OF IMMUNOTHERAPY (2007)
From traditional Chinese medicine to rational cancer therapy
Thomas Efferth et al.
TRENDS IN MOLECULAR MEDICINE (2007)
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis
Zachary J. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation
Xinshou Ouyang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection
Monica C. Panelli et al.
GENOME BIOLOGY (2007)
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors
Kenya Honda et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma
AS Jassar et al.
CANCER RESEARCH (2005)
Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death
GD Hu et al.
CANCER RESEARCH (2005)
The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling
A Schoenemeyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors
A Takaoka et al.
NATURE (2005)
Selection and validation of endogenous reference genes using a high throughput approach -: art. no. 55
P Jin et al.
BMC GENOMICS (2004)
Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes
BJ Barnes et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
IFNα sensitizes ME-180 human cervical cancer cells to TNFα-induced apoptosis by inhibiting cytoprotective NF-κ-B activation
K Suk et al.
FEBS LETTERS (2001)
Interferon γ (IFNγ) and tumor necrosis factor α synergism in ME-180 cervical cancer cell apoptosis and necrosis : IFNγ inhibits cytoprotective NF-κB through STAT1/IRF-1 pathways
K Suk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
